meta
|
evidence
oncology
Living systematic review and meta-analysis
castration-resistant prostate cancer (CRPC)
metastatic (mCRPC) - 1st line (L1)
3
metastatic (mCRPC) - 2nd line (L2)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
anti-PD-(L)1
pembrolizumab based treatment
versus all
vs chemotherapy
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded